Literature DB >> 25788435

Cannabinoid abuse and addiction: Clinical and preclinical findings.

L V Panlilio1, S R Goldberg1, Z Justinova1.   

Abstract

Cannabinoid abuse disorders represent a widespread public health issue, but there are no approved medications for their treatment. This review describes efforts to understand the mechanisms of cannabinoid abuse and its adverse effects, to identify molecular targets for pharmacotherapy, and to evaluate potential treatments in human volunteers and animal models of cannabinoid reward, withdrawal, and relapse.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25788435      PMCID： PMC4446186          DOI： 10.1002/cpt.118

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  74 in total

1.  Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.

Authors:  P M Beardsley; B R Martin
Journal:  Eur J Pharmacol       Date:  2000-01-03       Impact factor: 4.432

2.  Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids.

Authors:  Paulina Carriba; Oskar Ortiz; Kshitij Patkar; Zuzana Justinova; Jessica Stroik; Andrea Themann; Christa Müller; Anima S Woods; Bruce T Hope; Francisco Ciruela; Vicent Casadó; Enric I Canela; Carme Lluis; Steven R Goldberg; Rosario Moratalla; Rafael Franco; Sergi Ferré
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

3.  Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice.

Authors:  William S Hyatt; William E Fantegrossi
Journal:  Behav Pharmacol       Date:  2014-06       Impact factor: 2.293

4.  Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Authors:  Timothy W Lefever; Julie A Marusich; Kateland R Antonazzo; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2014-01-09       Impact factor: 3.533

Review 5.  Acute and long-term effects of cannabis use: a review.

Authors:  Laurent Karila; Perrine Roux; Benjamin Rolland; Amine Benyamina; Michel Reynaud; Henri-Jean Aubin; Christophe Lançon
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration.

Authors:  Daniele Lecca; Fabio Cacciapaglia; Valentina Valentini; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2006-07-19       Impact factor: 4.530

7.  Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.

Authors:  Marcello Solinas; Maria Scherma; Gianluigi Tanda; Carrie E Wertheim; Walter Fratta; Steven R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2007-03-09       Impact factor: 4.030

8.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

9.  Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.

Authors:  Zuzana Justinova; Patrik Munzar; Leigh V Panlilio; Sevil Yasar; Godfrey H Redhi; Gianluigi Tanda; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2008-02-27       Impact factor: 7.853

Review 10.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492
View more
  24 in total

Review 1.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

2.  Effects of morphine/CP55940 mixtures on an impulsive choice task in rhesus monkeys.

Authors:  Vanessa Minervini; Charles P France
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

3.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

4.  DAKB-GPCRs: An Integrated Computational Platform for Drug Abuse Related GPCRs.

Authors:  Maozi Chen; Yankang Jing; Lirong Wang; Zhiwei Feng; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2019-03-14       Impact factor: 4.956

5.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

Review 6.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

7.  Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids.

Authors:  Kenta Kuramoto; Nan Wang; Yuying Fan; Weiran Zhang; Frank J Schoenen; Kevin J Frankowski; Juan Marugan; Yifa Zhou; Sui Huang; Congcong He
Journal:  Autophagy       Date:  2016-06-15       Impact factor: 16.016

Review 8.  New vistas on cannabis use disorder.

Authors:  Miriam Melis; Roberto Frau; Peter W Kalivas; Sade Spencer; Vivian Chioma; Erica Zamberletti; Tiziana Rubino; Daniela Parolaro
Journal:  Neuropharmacology       Date:  2017-03-31       Impact factor: 5.250

9.  Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.

Authors:  Charles W Schindler; Godfrey H Redhi; Kiran Vemuri; Alexandros Makriyannis; Bernard Le Foll; Jack Bergman; Steven R Goldberg; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2016-02-18       Impact factor: 7.853

10.  Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats.

Authors:  Abhigyan Ravula; Hardik Chandasana; Darin Jagnarine; Shannon C Wall; Barry Setlow; Marcelo Febo; Adriaan W Bruijnzeel; Hartmut Derendorf
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.